GRI918013 is a compound that selectively and competitively inhibits the autocrine motility factor (ATX/NPP2), thereby suppressing tumor cell invasion and metastasis. GRI918013 binds competitively to the active site of ATX, preventing the entry of lipid substrates such as lysophosphatidylcholine (LPC). This reduces the ATX-catalyzed hydrolysis of LPC to form lysophosphatidic acid (LPA), thereby inhibiting cell invasion and metastasis associated with the ATX-LPA axis. GRI918013 exhibits an inhibitory effect on the ATX-catalyzed hydrolysis of the LPL substrate FS-3, with an IC50 of 31.42 nM and a Ki of 12.98 nM. GRI918013 can serve as a tool for studying invasion and metastasis in cancers such as melanoma, and is also suitable for research on ATX-LPA axis-related diseases, including fibrotic diseases, neuropathic pain, and cholestatic pruritus.
Molecular Weight:
433.28
Purity:
99.80%
CAS Number:
[313685-55-1]
Formula:
C17H15Cl2FN2O4S
Target:
PDE
T27433
T27433
* VAT and and shipping costs not included. Errors and price changes excepted
